NAT10 and cancer: By using bifunctional moleculesthat simultaneously bind to an E3 ligase and a target protein, PROTACsfacilitate ubiquitination and proteasomal degradation.−,  This “event-driven” mechanism offers advantages likeimproved selectivity, overcoming resistance, and reducing off-targettoxicity. PROTACs have shown efficacyagainst oncogenic proteins such as BRD4, NSD3, FOXM1, and STAT3, positioningthem as promising candidates for modulating NAT10 in cancer therapy.−, ,